Collectively, these results mechanistically linked the miR‐19a‐3p/BAMBI/TGF‐β1 axis to CD4+ T cell dysfunction in HBx‐overexpressing DLBCL and provided preclinical evidence for TGF‐β‐targeted immunotherapy to counteract immune escape. This evidence concerns the gene CD4 and diffuse large B-cell lymphoma.